<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390986</url>
  </required_header>
  <id_info>
    <org_study_id>LON002-003</org_study_id>
    <nct_id>NCT02390986</nct_id>
  </id_info>
  <brief_title>An Extension Study of LON002 in Patients With Cancer</brief_title>
  <official_title>An Extension Study of LON002 in Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LondonPharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LondonPharma Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the long term safety and efficacy of
      LON002.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an extension study of LON002 in patients with cancer, who have completed other London
      Pharma sponsored LON002 studies (parent study). It provides the opportunity for patients to
      continue receiving treatment for as long as the patient continues to derive a clinical
      benefit.

      Long term safety and efficacy will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Adverse Events grade â‰¥3 related to LON002 and Serious Adverse Events related to LON002 as a measure of safety and tolerability.</measure>
    <time_frame>Participants will be followed for the duration of their study treatment, an expected average of 6 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solid Tumours</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LON002</intervention_name>
    <description>Extension study to provide continuing access to LON002 medication.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent;

          2. Has completed a LondonPharma sponsored parent trial of LON002 and continues to have
             clinical benefit in the judgement of the investigator;

          3. Eligible for continuation of LON002 treatment at the end of the parent trial,
             according to the parent trial protocol;

          4. Able to comply with the protocol LON002-003;

          5. Women of child bearing potential must have a negative pregnancy test before the start
             of treatment;

          6. Sexually active women of childbearing potential must be using an acceptable form of
             contraception for the duration of dosing and for 30 days thereafter;

          7. Male subjects with female partners of childbearing potential should use condoms for
             the duration of dosing and for 30 days thereafter

        Exclusion Criteria:

          1. Has not completed a LondonPharma sponsored parent trial of LON002;

          2. Unequivocal evidence of disease progression;

          3. Unacceptable toxicity experienced in the parent trial;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debashis Sarker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mazhar Ajaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Surrey County Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daryl Bendel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Xidea Solutions Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Laskow-Pooley</last_name>
    <phone>01865 784485</phone>
    <email>davidlaskow-pooley@londonpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mazhar Ajaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Debashis Sarker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Malignant Neoplasm</keyword>
  <keyword>Anti-cancer drug</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

